Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

August 10, 2022 04:02 PM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication...

Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer

The ongoing real-world Prospective Clinicogenomic (PCG) Study compares the clinical actionability of both tissue- and blood-based comprehensive genomic profiling to limited tissue testing in this patient population August 08, 2022...

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

August 08, 2022 06:15 AM Eastern Daylight Time PALO ALTO, Calif., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC)...